Pressmeddelande

BioStock: Robust data drives Alligator Bioscience forward

Cision Publicerad: 30 Oct 12:03

Alligator Bioscience has certainly had a successful 2024 according to its Q3 report. With promising phase II results from its leading drug candidate mitazalimab, strong partnerships, and a clear strategy for the future, the company is poised to make significant strides in cancer treatment. Alligator is continuing to invest in preparing mitazalimab for phase III, to be able to initiate a trial in H1 2025, while maturing its ongoing dialogue with global pharma companies regarding a potential partnership.

Read the article about Alligator Bioscience at biostock.se:

https://www.biostock.se/en/2024/10/robust-data-drives-alligator-bioscience-forward/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Alligator Bioscience

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!